CM
CABA icon

Crestline Management’s Cabaletta Bio CABA Stock Holding History

Crestline Management’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-143,575
Closed -$678K – 739
2024
Q3 		$678K Buy
143,575
+38,870
+37% +$225K 0.04% 329
2024
Q2 		$783K Buy
104,705
+19,705
+23% +$242K 0.06% 156
2024
Q1 		$1.45M Buy
+85,000
New +$1.82M 0.13% 143
2023
Q1 		– Sell
-22,107
Closed -$204K – 165
2022
Q4 		$204K Buy
22,107
+226
+1% +$823 0.03% 156
2022
Q3 		$14K Hold
21,881
– – ﹤0.01% 201
2022
Q2 		$23K Buy
+21,881
New +$30.9K ﹤0.01% 221

Other funds holding CABA

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Crestline Management's CABA Position: Q4 2024 in Review

Crestline Management sold out of Cabaletta Bio (CABA) in Q4 2024, closing a stake of 143,575 shares — an estimated $678K sold.

Crestline Management first reported a position in CABA in Q2 2022 and held it in 6 quarters. The position peaked at $1.45M in Q1 2024. 108 funds tracked by Wall St. Rank hold CABA as of Q4 2024.

  • Crestline Management reported no remaining Cabaletta Bio position as of Q4 2024 after selling out during the quarter.
  • Crestline Management sold 143,575 Cabaletta Bio shares in Q4 2024, an estimated $678K.
  • Crestline Management first reported a position in Cabaletta Bio in Q2 2022 and held it in 6 quarters.
  • Crestline Management's Cabaletta Bio position peaked at $1.45M in Q1 2024.
  • 108 funds tracked by Wall St. Rank held Cabaletta Bio as of Q4 2024.

Based on Crestline Management's 13F filing for Q4 2024, filed 14 Feb 2025.